Tumor lysates from all animals receiving olaparib treatment had greatly reduced PAR levels after short-term (28 hrs; p<0.01 for line 32233, p<0.001 for line 30200) and long-term (2 weeks; p<0.01 for line 29255 and 30200, p<0.0001 for line 39877) dosing compared to mice treated with vehicle or cisplatin (Fig. 3B, C), indicating that tumor exposure to olaparib was sufficient for PARP inhibition. This evidence concerns the gene PARP1 and neoplasm.